FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933906333> ?p ?o ?g. }

• W2933906333 endingPage "1724" @default.
• W2933906333 startingPage "1715" @default.
• W2933906333 abstract "Abstract Aims Little is known about whether sodium intake is associated with the clinical effects of SGLT2 inhibitors (SGLT2is); however, SGLT2is may increase urinary sodium excretion. Thus, we investigated the impact of daily sodium intake on the estimated glomerular filtration rate (eGFR) via an SGLT2i, tofogliflozin (TOFO), in patients with type 2 diabetes (T2D). Methods Individual‐level data on 775 T2D patients in TOFO Phase 3 trials were analysed. Adjusted changes in variables during 52 weeks of TOFO therapy were compared according to basal daily salt intake (DSI), which was measured based on estimated daily urinary sodium excretion using the Tanaka formula. Multivariable analysis was used to investigate the impact of basal DSI on changes in eGFR at Weeks 4 and 52. Results Sixty‐six percent of participants were men; mean age, HbA1c, body mass index, eGFR MDRD and median DSI were 58.5 years, 8.0%, 25.6 kg/m 2 , 83.9 mL/min/1.73 m 2 and 9.3 g/d, respectively. In all participants, eGFR MDRD sharply dipped during Week 4, and gradually increased by Week 52, showing a significant increase overall from baseline to Week 52. Multivariable analysis showed that basal DSI and HbA1c levels were independently correlated with eGFR MDRD changes at Weeks 4 and 52. Additionally, lower baseline HbA1c and DSI levels were significantly correlated with a greater increase in eGFR MDRD at Week 52. Conclusions Dietary salt intake, in addition to glycaemic control, correlates with changed eGFR MDRD via TOFO. Thus, an appropriate dietary approach to therapy should be considered before treatment of T2D patients with an SGLT2i." @default.
• W2933906333 created "2019-04-11" @default.
• W2933906333 creator A5001368676 @default.
• W2933906333 creator A5012076071 @default.
• W2933906333 creator A5030118011 @default.
• W2933906333 creator A5036190568 @default.
• W2933906333 creator A5066138488 @default.
• W2933906333 date "2019-05-06" @default.
• W2933906333 modified "2023-10-16" @default.
• W2933906333 title "Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status" @default.
• W2933906333 cites W1968079616 @default.
• W2933906333 cites W1973273635 @default.
• W2933906333 cites W1990025047 @default.
• W2933906333 cites W2027545319 @default.
• W2933906333 cites W2033212729 @default.
• W2933906333 cites W2045181376 @default.
• W2933906333 cites W2055864845 @default.
• W2933906333 cites W2058591002 @default.
• W2933906333 cites W2067949126 @default.
• W2933906333 cites W2070474257 @default.
• W2933906333 cites W2080006254 @default.
• W2933906333 cites W2097620901 @default.
• W2933906333 cites W2108588975 @default.
• W2933906333 cites W2118625269 @default.
• W2933906333 cites W2128814368 @default.
• W2933906333 cites W2130251488 @default.
• W2933906333 cites W2139634859 @default.
• W2933906333 cites W2146264128 @default.
• W2933906333 cites W2147663252 @default.
• W2933906333 cites W2149082335 @default.
• W2933906333 cites W2152189242 @default.
• W2933906333 cites W2155287847 @default.
• W2933906333 cites W2155793865 @default.
• W2933906333 cites W2155965977 @default.
• W2933906333 cites W2165733654 @default.
• W2933906333 cites W2238341693 @default.
• W2933906333 cites W2409027410 @default.
• W2933906333 cites W2424539745 @default.
• W2933906333 cites W2512006388 @default.
• W2933906333 cites W2553261268 @default.
• W2933906333 cites W2561556991 @default.
• W2933906333 cites W2586772356 @default.
• W2933906333 cites W2588592529 @default.
• W2933906333 cites W2599208859 @default.
• W2933906333 cites W2626446274 @default.
• W2933906333 cites W2733849831 @default.
• W2933906333 cites W2795321793 @default.
• W2933906333 cites W2898388822 @default.
• W2933906333 cites W2900413769 @default.
• W2933906333 doi "https://doi.org/10.1111/dom.13731" @default.
• W2933906333 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6619387" @default.
• W2933906333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30945431" @default.
• W2933906333 hasPublicationYear "2019" @default.
• W2933906333 type Work @default.
• W2933906333 sameAs 2933906333 @default.
• W2933906333 citedByCount "5" @default.
• W2933906333 countsByYear W29339063332021 @default.
• W2933906333 countsByYear W29339063332022 @default.
• W2933906333 countsByYear W29339063332023 @default.
• W2933906333 crossrefType "journal-article" @default.
• W2933906333 hasAuthorship W2933906333A5001368676 @default.
• W2933906333 hasAuthorship W2933906333A5012076071 @default.
• W2933906333 hasAuthorship W2933906333A5030118011 @default.
• W2933906333 hasAuthorship W2933906333A5036190568 @default.
• W2933906333 hasAuthorship W2933906333A5066138488 @default.
• W2933906333 hasBestOaLocation W29339063331 @default.
• W2933906333 hasConcept C10146269 @default.
• W2933906333 hasConcept C126322002 @default.
• W2933906333 hasConcept C126894567 @default.
• W2933906333 hasConcept C134018914 @default.
• W2933906333 hasConcept C159641895 @default.
• W2933906333 hasConcept C178790620 @default.
• W2933906333 hasConcept C185592680 @default.
• W2933906333 hasConcept C2777180221 @default.
• W2933906333 hasConcept C2778024521 @default.
• W2933906333 hasConcept C2780221984 @default.
• W2933906333 hasConcept C44249647 @default.
• W2933906333 hasConcept C537181965 @default.
• W2933906333 hasConcept C555293320 @default.
• W2933906333 hasConcept C71924100 @default.
• W2933906333 hasConcept C77411442 @default.
• W2933906333 hasConcept C90924648 @default.
• W2933906333 hasConceptScore W2933906333C10146269 @default.
• W2933906333 hasConceptScore W2933906333C126322002 @default.
• W2933906333 hasConceptScore W2933906333C126894567 @default.
• W2933906333 hasConceptScore W2933906333C134018914 @default.
• W2933906333 hasConceptScore W2933906333C159641895 @default.
• W2933906333 hasConceptScore W2933906333C178790620 @default.
• W2933906333 hasConceptScore W2933906333C185592680 @default.
• W2933906333 hasConceptScore W2933906333C2777180221 @default.
• W2933906333 hasConceptScore W2933906333C2778024521 @default.
• W2933906333 hasConceptScore W2933906333C2780221984 @default.
• W2933906333 hasConceptScore W2933906333C44249647 @default.
• W2933906333 hasConceptScore W2933906333C537181965 @default.
• W2933906333 hasConceptScore W2933906333C555293320 @default.
• W2933906333 hasConceptScore W2933906333C71924100 @default.
• W2933906333 hasConceptScore W2933906333C77411442 @default.
• W2933906333 hasConceptScore W2933906333C90924648 @default.

• next